Clinical Trial

An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.
Protocol Amendment History 4 changes
notable Trial sites expanded: 7 -> 10 locations 2026-08-11
notable Trial sites expanded: 4 -> 7 locations 2026-08-05
notable Trial sites expanded: 1 -> 4 locations 2026-07-09
critical Recruitment opened 2026-07-01
Trial Details
NCT Number NCT07619287
Lead Sponsor BeOne Medicines
Conditions Myeloid Malignancy
Enrollment 118 participants
Start Date 2026-06-23
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-10